It Paid Doctors Kickbacks. Now, Novartis Will Pay a $678 Million Settlement. - The New York Times
Novartis' Patent On Diabetes Drug Vildagliptin Expires Tomorrow, Prices To Fall By 60%
New drugs help Novartis shrug off Gleevec competition - PMLiVE
Novartis - Wikipedia
Cipla, Novartis AG ink agreement on diabetes therapy Galvus - The Hindu BusinessLine
Cipla & Novartis AG Ink Pact on Diabetes Drug Galvus | NAVLIN DAILY
Novartis reaches $678 million settlement of U.S. fraud lawsuit
Merck, Novartis battling for diabetes market - May. 24, 2006
Cipla in pact with Novartis Pharma for diabetes drug Galvus - Drug Discovery & Development
NeoBiocon partners Novartis to launch diabetes drugs in UAE - The Economic Times
Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug
Cipla Signs Licence Agreement With Novartis Ag To Manufacture And Market Type-2 Diabetes Medicine
NeoBiocon Partners Novartis to Launch Diabetes Drugs in UAE
Price of key diabetes drug may crash as Novartis risks losing patent
Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis | Fierce Pharma
After trial flop, EU officials taking a closer look at Novartis' Adakveo
Cancer Drug for Diabetes? | Science | AAAS
Cipla signs pact with Novartis Pharma AG for diabetes drug Galvus - The Hindu
Natco challenges Novartis; claims right to manufacture diabetes drug - Times of India
Coronaimpfstoff: Novartis unterzeichnet neuen Deal mit Biontech
Novartis sues Biocon over anti-diabetes drug vildagliptin: Bitter pill? – Spicyip
Patients or patents? | Mint
Sanofi schmiedet millionenschwere Diabetes-Allianz mit Google | Reuters
Type 2 diabetes: Antipsychotic medications may help lower blood sugar
